N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists

1 . A compound of formula (I):

wherein:

G is a COOH group or a tetrazolyl group;

R1 and R2 are each independently chosen from hydrogen atoms, and alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, and heteroarylalkynyl groups;

or R1 and R2 form, together with the nitrogen atom to which they are attached, either a 3- to 14-membered monocyclic or polycyclic heterocyclic ring system or a 5- to 14-membered heteroaryl group;

wherein each of said 3- to 14-membered monocyclic or polycyclic heterocyclic ring system, or 5- to 14-membered heteroaryl group comprises from 1 to 5 heteroatoms chosen from nitrogen, oxygen and sulphur;

wherein each of said alkyl, alkenyl, and alkynyl groups is independently unsubstituted or substituted with one to four substituents, wherein said one to four substituents may be the same or different and each is independently chosen from Ra;

and wherein each of said cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently unsubstituted or substituted with one to four substituents, wherein said one to four substituents may be the same or different and each is independently chosen from Rb;

R3 and R4 are each independently chosen from hydrogen atoms and alkyl groups having from 1 to 6 carbon atoms;

R5 is chosen from 6- to 14-membered monocyclic or polycyclic aryl groups and 5- to 14-membered monocyclic or polycyclic heteroaryl groups comprising from 1 to 5 heteroatoms chosen from nitrogen, oxygen and sulphur;

wherein each of said aryl and heteroaryl groups or moieties is independently unsubstituted or substituted with one to four substituents, wherein said one to four substituents may be the same or different and each is independently chosen from Rb;

R6 is a group chosen from —OH, —ORc, —NO 2 , halogen, —S(O)Rc, —S(O) 2 Rc, —SRc, —S(O) 2 ORc, —S(O)NRcRc —S(O) 2 NRcRc, —NRcRc, —O(CRcRc)mNRcRc, —C(O)Rc, —CO 2 Rc, —CO 2 (CRcRc)mCONRcRc, —OC(O)Rc, —CN, —C(O)NRcRc, —NRcC(O)Rc, —OC(O)NRcRc, —NRcC(O)ORc, —NRcC(O)NRcRc, —CRc(N—ORc), —CFH 2 , —CF 2 H, —Ra, —CF 3 , alkyl, alkenyl and alkynyl;

n is an integer from 0 to 3

Ra is a group chosen from alkyl, —OH, —ORc, —NO 2 , halogen, —S(O)Rc, —S(O) 2 Rc, —SRc, —S(O) 2 ORc, S(O)NRcRc, —S(O) 2 NRcRc, —NRcRc, —O(CRcRc)mNRcRc, —C(O)Rc, —CO 2 Rc, —CO 2 (CRcRc)mCONRcRc, —OC(O)Rc, —CN, —C(O)NRcRc, —NRcC(O)Rc, —OC(O)NRcRc, —NRcC(O)ORc, —NRcC(O)NRcRc, —CRc(N—ORc), —CFH 2 , —CF 2 H, —Ra, and —CF 3 ; wherein if two or more Rc groups are present these Rc groups may be the same or different;

Rb is a group chosen from —OH, —ORd, —NO 2 , halogen, —S(O)Rd, —S(O) 2 Rd , —SRd, —S(O) 2 ORd, —S(O)NRdRd, —S(O) 2 NRdRd, —NRdRd, —O(CRdRd)mNRdRd, —C(O)Rd, —CO 2 Rd, —CO 2 (CRdRd)mCONRdRd, —OC(O)Rd, —CN, —C(O)NRdRd, —NRdC(O)Rd, —OC(O)NRdRd, —NRdC(O)ORd, —NRdC(O)NRdRd, —CRd(N—ORd), —CFH 2 , —CF 2 H, —Ra, —CF 3 , alkyl, alkenyl, C 2-4 alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently unsubstituted or substituted with one to four substituents; wherein said one to four substituents may be the same or different and each is independently chosen from Ra;

L1 is either a direct bond or a group chosen from N(Rc)-, —O—, —N(Rc)CO—, —CON(Rc)-, —O(CO)N(Rc)- and —N(Rc)(CO)O—;

Rc is a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms;

Rd is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, or heteroarylalkynyl;

wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl groups is independently unsubstituted or substituted with one to four substituents; wherein said one to four substituents may be the same or different and each is independently chosen from Re;

Re is a group chosen from alkyl, —OH, —ORc, —NO 2 , halogen, —S(O)Rc, —S(O) 2 Rc, —SRc, —S(O) 2 ORc, —S(O)NRcRc, —S(O) 2 NRcRc, —NRcRc, —O(CRcRc)mNRcRc, —C(O)Rc, —CO 2 Rc, —CO 2 (CRcRc)mCONRcRc, —OC(O)Rc, —CN, —C(O)NRcRc, —NRcC(O)Rc, —OC(O)NRcRc, —NRcC(O)ORc, —NRcC(O)NRcRc, —CRc(N—ORc), —CFH 2 , —CF 2 H, —Ra, or —CF 3 ; wherein if two or more Rc groups are present these Rc groups may be the same or different;

or pharmaceutically acceptable salt thereof;

or, when G is a carboxylic group in a compound of formula (I) or in a pharmaceutically acceptable salt of a compound of formula (I), a compound resulting from the esterification, with an alcohol, of said carboxylic group; or a pharmaceutically acceptable salt thereof.

2 . A compound according to claim 1 , wherein G is a COOH group or a compound resulting from the esterification, with an alcohol, of the COOH group.

3 . A compound according to claim 1 , wherein R3 and R4 are hydrogen atoms.

4 . A compound according to claim 1 , wherein R1 and R2 are each independently chosen from hydrogen atoms, alkyl, cycloalkyl, heterocyclylalkyl, aryl, arylalkyl, and heteroarylalkyl groups, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups is independently unsubstituted or substituted;

or R1 and R2 form, together with the nitrogen atom to which they are attached, a 5- to 8-membered monocyclic heterocyclic ring system wherein said ring system comprises from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulphur; and wherein said ring system is unsubstituted or substituted.

5 . A compound according to claim 1 , wherein R5 is chosen from a 6- to 14-membered monocyclic or polycyclic aryl and a 5- to 14-membered monocyclic or polycyclic heteroaryl groups comprising from 1 to 5 heteroatoms chosen from nitrogen, oxygen and sulphur, wherein each of said aryl and heteroaryl groups is independently unsubstituted or substituted.

6 . A compound according to claim 5 , wherein each of said aryl and heteroaryl groups is independently unsubstituted or substituted by one or more halogen atoms.

7 . A compound according to claim 1 , wherein L1 is a group chosen from —NH—, —O— and —NHCO—.

8 . A compound according to claim 1 , wherein R5-L1- is chosen from benzamide, isonicotinamide, 2,6-naphthyridin-1-ylamino, 2,7-naphthyridin-1-ylamino; 2,6-naphthyridin-1-yloxy and 2,7-naphthyridin-1-yloxy wherein said groups are unsubstituted or substituted.

9 . A compound according to claim 1 , wherein n is zero.

10 . A compound according to claim 1 chosen from:

(2S)-2-{[(tert-butylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-2-(N-benzylaminosulfonilamino)-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionate

(2S)-2-(N-benzylaminosulfonilamino)-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid

Methyl (2S)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino}propionate

(2S)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino}propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dimethylamino)sulfonyl]amino}propionic acid

Methyl (2S)-3-(4-{[1-(2,6-dichlorophenyl)methanoyl]amino}phenyl)-2-(piperidine-1-sulfonylamino)propionate

(2S)-3-(4-{[1-(2,6-dichlorophenyl)methanoyl]amino}phenyl)-2-(piperidine-1-sulfonylamino)propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisobutylamino)sulfonyl]amino}propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisobutylamino)sulfonyl]amino}propionic acid

Methyl (2S)-2-({[benzyl(ethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

(2S)-2-{[(benzylethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dibutylamino)sulfonyl]amino}propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(dibutylamino)sulfonyl]amino}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[[2-(3,4-dimethoxyphenyl)ethyl]isobutylamino]sulfonyl}amino)propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[[2-(3,4-dimethoxyphenyl)ethyl]isobutylamino]sulfonyl}amino)propionic acid

Methyl (2S)-2-({[bis(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

(2S)-2-({[bis(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[methyl(2-pyridin-2-ylethyl)amino]sulfonyl}amino)propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[methyl(2-pyridin-2-ylethyl)amino]sulfonyl}amino)propionic acid

Methyl (2S)-2-{[(cyclohexylmethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

(2S)-2-{[(cyclohexylmethylamino)sulfonyl]amino}-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[(3-methylbutyl)(thien-2-ylmethyl)amino]sulfonyl}amino)propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[(3-methylbutyl)(thien-2-ylmethyl)amino]sulfonyl}amino)propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(piperidin-1-ylsulfonyl)amino]propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(piperidin-1-ylsulfonyl)amino]propionic acid

Methyl (2S)-2-[(azepan-1-ylsulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

(2S)-2-[(azepan-1-ylsulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(morpholin-4-ylsulfonyl)amino]propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(morpholin-4-ylsulfonyl)amino]propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(thiomorpholin-4-ylsulfonyl)amino]propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[(thiomorpholin-4-ylsulfonyl)amino]propionic acid

Methyl (2S)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate

(2S)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid

Methyl (2S)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate

(2S)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid

Methyl (2S)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate

(2S)-2-{[(diisobutylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid

Methyl (2S)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionate

(2S)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisopropylamino)sulfonyl]amino}propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(diisopropylamino)sulfonyl]amino}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}propionic acid

Methyl (2S)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate

(2S)-2-{[(dimethylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid

Methyl (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate

(2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid

Methyl (2S)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate

(2S)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid

Methyl (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate

(2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid

Methyl (2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate

(2S)-2-{[(diisopropylamino)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid

Methyl (2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionate

(2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-ylamino)phenyl]propionic acid

Methyl (2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate

(2S)-2-{[(2,6-dimethylpiperidin-1-yl)sulfonyl]amino}-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid

Methyl (2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionate

(2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionic acid

Methyl (2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

(2S)-2-({[benzyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

(2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichlorobenzoyl)amino]phenyl}propionate

(2S)-2-({[isopropyl(thien-2-ylmethyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichlorobenzoyl)amino]phenyl}propionic acid

Methyl (2S)-3-{4-[(2,6-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1S)-1-phenylethyl]amino}sulfonyl)amino]propionate

(2S)-3-{4-[(2,6-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1S)-1-phenylethyl]amino}sulfonyl)amino]propionic acid

Methyl (2S)-2-({[cyclopentyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate

(2S)-2-({[cyclopentyl(isopropyl)amino]sulfonyl}amino)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[isobutyl(isopropyl)amino]sulfonyl}amino)propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-({[isobutyl(isopropyl)amino]sulfonyl}amino)propionic acid

Methyl (2S)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionate

(2S)-2-({[cyclohexyl(isopropyl)amino]sulfonyl}amino)-3-[4-(2,6-naphthyridin-1-yloxy)phenyl]propionic acid

Methyl (2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1R)-1-phenylethyl]amino}sulfonyl)amino]propionate

(2S)-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}-2-[({isobutyl[(1R)-1-phenylethyl]amino}sulfonyl)amino]propionic acid

Methyl (2S)-2-({[methyl(phenyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionate

(2S)-2-({[methyl(phenyl)amino]sulfonyl}amino)-3-{4-[(2,6-dichlorobenzoyl)amino]phenyl}propionic acid

Methyl (2S)-({[2-(phenylsulfonyl)phenyl]amino}sulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionate; and

(2S)-({[2-(phenylsulfonyl)phenyl]amino}sulfonyl)amino]-3-{4-[(3,5-dichloroisonicotinoyl)amino]phenyl}propionic acid;

or a pharmaceutically acceptable salt thereof.

11 . A process for producing a compound of claim 1 , comprising reacting an amine of formula (III):

with a corresponding sulfamoyl chloride of formula (IV):

to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

12 . A process for producing a compound of claim 1 , comprising reacting an amine of formula (IIa):

with an amine of formula (V)

to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

13 . A process for producing a compound of claim 1 , comprising reacting an amine of formula (III):

with a sulfamide of formula (VII):

to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

14 . A process for producing a compound of claim 1 , comprising:

reacting an amine of formula (III):

with tert-butanol and chlorosulfonyl isocyanate to yield the sulfamide of formula (VIII);

reacting the sulfamide of formula (VIII) with an alcohol of formula (IX)

R2-OH  (IX)

to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

15 . A process for producing a compound of claim 1 , comprising reacting an amine of formula (X):

with an amine of formula (V)

to produce a compound of formula (I); and

optionally producing a pharmaceutically acceptable salt of a compound of formula (I).

16 . (canceled)

17 . (canceled)

18 . (canceled)

19 . (canceled)

20 . A pharmaceutical composition comprising an effective amount of a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

21 . A compound or a pharmaceutically acceptable salt thereof as defined in claim 1 , for use in a method of treatment of a subject afflicted with a pathological condition susceptible to amelioration by antagonism of α4β1 and/or α4β7 integrins.

22 . A method for treating a subject afflicted with a pathological condition susceptible to amelioration by antagonism of α4β1 and/or α4β7 integrins, comprising administering to said subject an effective amount of a compound as defined in claim 1 .

23 . A method according to claim 22 , wherein the pathological condition is susceptible to amelioration by the inhibition or prevention of cell adhesion processes mediated by α4β1 and/or α4β7 integrins.

24 . A method according to claim 22 , wherein the pathological condition is an immune or inflammatory disease or disorder susceptible to amelioration by antagonism of α4β1 and/or α4β7 integrins.

25 . A method according to claim 22 , wherein the pathological condition or disease is chosen from multiple sclerosis, asthma, allergic rhinitis, allergic conjunctivitis, an inflammatory lung disease, rheumatoid arthritis, polydermatomyositis, septic arthritis, type I diabetes, rejection following organ transplantation, restenosis, rejection following autologous bone marrow transplantation, inflammatory sequelae of viral infections, atopic dermatitis, myocarditis, inflammatory bowel disease including ulcerative colitis and Crohn's disease, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, psoriasis, tumor metastasis, atherosclerosis and cerebral ischemia.